Real-world study shows plaque psoriasis stays controlled after 2 ustekinumab biosimilar switches, with stable labs and no serious adverse events. Patients with moderate-to-severe plaque psoriasis who ...
The FDA approved Teva’s biosimilar for denosumab, and the FDA and EMA accepted its asthma biosimilar application for review. Denosumab-adet (Ponlimsi; Teva Pharmaceutical Industries) was approved by ...
Experts convened at the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology 2025 Annual Meeting in Seattle, Washington, from June 26 to 28, 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results